mounjaro and tirzepatide Lilly's new drug (tirzepatide ) wins US FDA approval Mounjaro is second obesity drug

Lindfors et al., 2020), as well as explaining the reasons to do (or not do) investigations (e.g., colonoscopy) (Black and Ford, 2020)

Serious risks include thyroid tumors and pancreatitis, requiring close monitoring

These gastrointestinal side effects are typically worse when starting treatment or after a dosage increase, but usually subside as the body adjusts to the medication within 4-8 weeks

The honest answer is that the human safety data is limited compared to decades-old pharmaceuticals, but the preclinical safety record across multiple species is unusually clean for a peptide with this level of biological activity

Ginger in tea or lozenges helps some people, and acupressure wristbands provide relief for others by stimulating the P6 point

2002;81(11 Suppl):S5269